2016 Press/Media Releases:

OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales

MIAMI--(BUSINESS WIRE) April 25, 2016 – OPKO Health, Inc. (NYSE:OPK) today announced the appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales to support the anticipated launch of RAYALDEE®.

Mr. DeMarco has over 30 years of commercial pharmaceutical experience with established large companies, such as Schering Plough, Amgen and Eisai, as well as emerging companies, and a career-long focus on specialty products and nephrology. Prior to joining OPKO, Mr. DeMarco served as a consultant providing commercial leadership services to pharmaceutical, medical device and healthcare services companies. Mr. DeMarco has built a number of sales organizations during his career in advance of anticipated product launches in a diverse group of therapeutic areas.

"Jim is uniquely qualified to establish and execute our commercial plans for RAYALDEE in the US. His deep knowledge of the chronic kidney disease market will help bring RAYALDEE to Stage 3 and 4 CKD patients," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. Dr. Frost continued, "We look forward to rapidly moving through the final regulatory steps with the FDA and securing an approval."

About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, a treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy.

OPKO Health, Inc.
Investor Relations:
Tara Mackay, 305-575-4100

Media
Rooney & Associates:
Terry Rooney, 212-223-0689 or Marion Janic, 212-223-4017

Investors
LHA:
Anne Marie Fields, 212-838-3777 or Bruce Voss, 310-691-7100

 
     
     
 
   

© 2018 OPKO Health Inc.- All rights reserved. | Privacy Policy | Terms Of Use